Merck Animal Health to Present Important New Data at the European Symposium of Porcine Health Management

Strong Focus on Evaluation of Vaccines for Porcine Circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae

MADISON, NEW JERSEY, April 21, 2015 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) will present results from more than 35 studies at the European Symposium of Porcine Health Management in Nantes, France from April 22-24, 2015. The majority of studies are focused on Porcine Circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae.

“Merck Animal Health, through our commitment to the Science of Healthier Animals™, is dedicated to providing veterinarians and pig producers with comprehensive solutions to manage the health of their herds,” said Narciso Bento, Global Swine Business, Merck Animal Health. “At ESPHM, we are pleased to share new state-of-the-art data that will help veterinarians and producers be more efficient and improve the management of the most serious and costly problems and diseases affecting pigs today.”

Abstracts selected for oral and poster presentations are as follows:

Oral Presentation

  • PCV efficacy with a new PCV2 and M. hyopneumoniae combination vaccine is independent of maternally derived immunity
  • First efficacy evaluation of a novel combination vaccine against Enzootic Pneumonia (Mycoplasma hyopneumoniae) and Porcine Circovirus type 2 (PCV2) under the influence of strong maternally derived PCV2 immunity in pigs
  • Use of busereline in nulliparous and multiparous sows: Effect on the reproductive system and in the weight variability of the resulting offspring

Poster Presentations
Herd Health Management

  • A clinical case study of swine respiratory complex involving PRRS, Mycoplasma and Ascaris (P040)
  • Validation of a PRRS serological diagnosis using sow colostrum (P100)
  • Evaluation of welfare aspects in suckling piglets after intradermal vaccine application with the IDAL injector (P018)
  • The Change in the Production Parameters in Swine Herds Vaccinating Against PRDC Between 2011-2014 (P152)
  • Vaccination in order to prevent pleuropneumonia caused by a non-typable actinobacillus pleuropneumoniae strain in Hungary (P251)
  • PCV2 serological status of sow herds and a possible relationship with reproductive disorders: an orientation study (P097)
  • Efficacy of Porcilis PCV M Hyo in reducing disease in a Spanish herd affected by post-weaning multi-systemic wasting syndrome (P112)
  • Piglet’s strategic vaccination: A tool to control PRRS infection in the nursery (P263)
  • Safety of Porcilis® PCV: effect of vaccination on growth performance during nursery period on a farm with a late PCV2 infection (P102)

Bacterial Diseases

  • Antibiotic reduction in a swine farm using a health plan (P125)
  • Comparison between liver spots and serological response in The SERASCA® text as a consequence of Ascaris suum infections in five Danish organic farms (P042)
  • Correlation between number of eggs and serological responses in The SERASCA® test due to Ascaris suum infections in five Danish organic farms (P142)
  • Contribution of SERASCA® serology and coprology to study the risk factors of internal parasitism of gilts in pig industrial farms (P038)
  • Efficacy of a novel E. coli/Clostridium vaccine: induction of protective antibodies (P265)

Immunology and Vaccinology

  • Practical experience after using IDAL as an alternative to traditional intramuscular vaccination in pigs (P262)
  • PCV-BacuCheck™, a new tool for evaluating PCV2 vaccination compliance (P254)
  • Field evaluation of a separate and combined vaccination against porcine reproductive and respiratory syndrome and Haemophilus parasuis in nursery pigs and serologic profiling of the vaccination groups (P250)
  • Assessment of the safety and immune response in gilts after intradermal application of Porcilis® PRRS by comparing two different application sites under field conditions (P243)
  • Serological response of APP unsuspicious gilts to vaccination with Porcilis® APP (P252)
  • Efficacy of a novel one shot combination vaccine against simultaneous Enzootic Pneumonia (Mycoplasma hyopneumoniae) and subclinical Porcine Circovirus (PCV2) infection under the influence of average maternally derived PCV2 immunity in pigs (P268)
  • Evaluation of the immune response to PCV2 vaccination in PRRSV viremic and non-viremic pigs (P249)
  • Efficacy of a new PCV2 and M. hyopneumoniae combination vaccine: field studies (P256)
  • Safety of a new PCV2 and M. hyopneumoniae combination vaccine: laboratory and field studies (P257)
  • Efficacy of a new PCV2 and M. hyopneumoniae combination vaccine: PCV2 challenge studies (P255)
  • Efficacy of a new PCV2 and M. hyopneumoniae combination vaccine: M. hyopneumoniae challenge studies (P258)
  • A field trial of Porcilis PCV 2 M Hyo in Hungary (P261)
  • Effect of Porcilis ® PCV vaccination on growth performance in late subclinical PCV2 infection (P099)
  • Effect of PRRS infection on PCV2 vaccination efficacy and measures to control the negative impact (P267)
  • Efficacy of tildipirosin to control H. parasuis infection in nursery (P211)
  • Efficacy of intradermal Mycoplasma vaccination compared to conventional control strategies (P143)
  • Impact of PCV2 vaccination on lymphoid lesions and physical performance of a non-vaccinated herd with subclinical PCV2 infection (P080)
  • Evaluation of two different vaccination programs for the control of respiratory disease on a farrow to finish farm in the UK (P137)
  • Serotyping of Erysipelothrix rhusiopathiae isolates from pigs in England and Wales from 1987 to 2012 (P202)
  • A comparison of the growth rate of PORCILIS PCV vaccinated pigs with that of controls in a PCV2 clinically free heard (P273)


  • Single fixed time insemination in a commercial farm using PORCEPTAL: A case report (P231)
  • Effect of fixed time insemination protocol on reduction of non-productive sow days (P234).

About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn and Twitter at @MerckAH.

Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (